Tris Pharma
Ejecutivos
Ver el organigrama con sus 16 ejecutivos principales
Biografías más buscadas en Tris Pharma
- Ketan Mehta, Chief Executive Officer and President
- Peter Ciano, Chief Financial Officer and Senior Vice President, Co...
- Cheryl Patnick, Senior Vice President, Human Resources and Adminis...
Recientes movimientos de ejecutivos en Tris Pharma
- Michael Magee, se ha incorporado a la empresa como Vice President, Quality and Compliance (noticia publicada el 8 de febrero de 2024).
- Franchesca Fowler, se ha incorporado a la empresa como Chief Compliance Officer, Vice President and General Counsel (noticia publicada el 22 de enero de 2024).
Crear su alerta
para seguir los movimientos de los ejecutivos en Tris Pharma.
Farmacia
Tris Pharma tiene 1.861 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacia
- MedMen has filed for bankruptcy protection (publicado el 28 de abril de 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado el 23 de marzo de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado el 19 de marzo de 2024).
Otros contactos sugeridos en el sector Farmacia
Noticias
Últimos comunicados de prensa de Tris Pharma
- Tris Pharma Launches Digital Health Business to Develop and Commercialize Digital Products for ADHD | Tris Pharma
- Tris Pharma Appoints Michael Magee as Vice President, Quality & Compliance | Tris Pharma
- Tris Pharma Appoints Franchesca Fowler to Chief Compliance Officer and Vice President, General Counsel | Tris Pharma
- Tris Pharma Partners with Perigon Pharmacy 360 to Enhance Access to DYANAVEL® XR Tablets for the Treatment of Attention Deficit Hyperactivity Disorder | Tris Pharma
- Tris Pharma Secures First ex-US Authorizations for Quillivant ER Oral Suspension and Quillivant ER Chewable Tablet for the Treatment of Attention Deficit Hyperactivity Disorder | Tris Pharma
- Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference | Tris Pharma
- Tris Pharma Awarded Five-Year Grant of Up to $16.6M From the NIH's National Institute on Drug Abuse to Advance Cebranopadol for the Treatment of Opioid Use Disorder | Tris Pharma
- Tris Pharma Expands Leadership Team as Company Broadens Commercial Portfolio and Progresses Clinical Pipeline | Tris Pharma
- Tris Pharma Announces FDA Approval of DYANAVEL® XR (amphetamine) Once-Daily Extended-Release Oral Tablets, CII, for ADHD | Tris Pharma
- Tris Pharma® Hires Seasoned Business Development Executive Anthony Amato joins as Executive Vice President Business Development – Generics Division | Tris Pharma
- View more press releases Close
Redes sociales sobre Tris Pharma
- Tris Pharma en Wikipedia, Google News y Yahoo Finance
- Tris Pharma en LinkedIn, Twitter y YouTube
Ponerse en contacto
Contactar a través de e-mail con sus ejecutivos Ketan Mehta 
Llame a Tris Pharma al +1 732...
